** Shares of drug developer BioAge Labs down ~70% to $6.13 premarket
** Brokerage Jefferies downgrades stock to "hold" from "buy"; lowers PT to $7 from $42
** New PT represents a 65.2% downside to Friday's close of $20.09
** Brokerage lowers PT on discontinuation of co's mid-stage obesity drug trial due to liver safety concerns
** Brokerage expects significant "stock drop"
** Brokerage also lowers co's drug pipeline value to $200 mln from $300 mln
** As of last close, stock has fallen 10.7% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。